NORGES BANK - PUMA BIOTECHNOLOGY INC ownership

PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 140 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2017. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.

Quarter-by-quarter ownership
NORGES BANK ownership history of PUMA BIOTECHNOLOGY INC
ValueSharesWeighting
Q1 2020$2,716,000
-14.5%
321,802
-11.4%
0.00%0.0%
Q4 2019$3,178,000
-34.3%
363,202
-19.1%
0.00%0.0%
Q3 2019$4,836,000
-41.9%
449,217
-31.5%
0.00%
-66.7%
Q2 2019$8,330,000
-67.2%
655,4370.0%0.00%
-62.5%
Q1 2019$25,425,000
+85.3%
655,437
-2.8%
0.01%
+60.0%
Q4 2018$13,719,000
-60.5%
674,177
-10.9%
0.01%
-54.5%
Q3 2018$34,708,000
-22.5%
756,9920.0%0.01%
-26.7%
Q2 2018$44,775,000
-22.9%
756,992
-11.3%
0.02%
-28.6%
Q1 2018$58,055,000
-18.0%
853,123
+19.2%
0.02%
-16.0%
Q4 2017$70,778,000
-7.4%
716,003
+12.2%
0.02%
-13.8%
Q3 2017$76,416,000
+74.4%
638,135
+27.3%
0.03%
+70.6%
Q2 2017$43,815,000
+199.8%
501,322
+27.6%
0.02%
+183.3%
Q1 2017$14,615,000
+90.0%
392,879
+56.8%
0.01%
+100.0%
Q4 2016$7,693,000
-38.8%
250,598
+27.7%
0.00%
-50.0%
Q3 2016$12,563,000
+239.4%
196,174
+57.9%
0.01%
+200.0%
Q2 2016$3,701,000
-29.1%
124,247
-30.1%
0.00%
-33.3%
Q1 2016$5,221,000
-67.8%
177,759
-14.1%
0.00%
-62.5%
Q4 2015$16,219,000
+4.0%
206,8760.0%0.01%0.0%
Q3 2015$15,590,000
-39.6%
206,876
-6.4%
0.01%
-38.5%
Q2 2015$25,816,000
-40.0%
221,123
+21.4%
0.01%
-38.1%
Q1 2015$42,998,000
+29.9%
182,112
+4.1%
0.02%
+23.5%
Q4 2014$33,103,000
-11.7%
174,901
+11.3%
0.02%
-15.0%
Q3 2014$37,475,000
+90.3%
157,081
-47.4%
0.02%
+300.0%
Q2 2014$19,696,000298,4240.01%
Other shareholders
PUMA BIOTECHNOLOGY INC shareholders Q1 2017
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 200,000$20,706,0006.01%
Redmile Group, LLC 230,673$23,882,0002.95%
WEATHERBIE CAPITAL, LLC 241,419$24,994,0002.31%
Tekla Capital Management LLC 185,820$19,238,0002.02%
Ghost Tree Capital, LLC 25,000$2,588,0001.59%
ADAGE CAPITAL PARTNERS GP, L.L.C. 5,686,668$588,741,0001.56%
Iguana Healthcare Management, LLC 25,000$2,588,0001.48%
Eventide Asset Management 42,100$4,359,0001.34%
Bain Capital Public Equity Management, LLC 401,330$41,550,0001.17%
Rock Springs Capital Management LP 31,500$3,261,0001.16%
View complete list of PUMA BIOTECHNOLOGY INC shareholders